Beneficial Pleiotropic Effects of Statins
Abstract
Background: Statins are recognised as the most effective lipid-lowering drugs. The main mechanism of action is the inhibition of 3-hydroxy- 3-methylglutaryl-coenzyme A reductase, which is a key enzyme in the cholesterol synthesis pathway. Statins also have additional effects, known as pleiotropic effects, which are mostly due to the inhibition of the formation of non-steroidal isoprenoids. The latter have important functions in the activation of many intracellular signalling pathways. Consequently, statins improve endothelial function, have anti-inflammatory and immunomodulatory activity, act as antioxidants, stabilize atherosclerotic plaques and influence haemostasis and thrombosis. The described mechanisms are particularly relevant in the protective activity of statins on the cardiovascular system, central nervous system, kidneys and many other organs. Conclusions: In the current article we review the pharmacological mechanisms of action, which contribute to the beneficial pleiotropic effects of statins. Described mechanisms are supported by the evidence obtained from clinical trials in the last decade.Downloads
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
